Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan
Despite the excellent antiviral effects of direct acting antivirals (DAAs) for hepatitis C virus (HCV) infection with subsequent decrease of morbidity and mortality, a small proportion (5%) of the treated patients do not respond to first-line DAAs and have persistent viremia. Rescue therapy for pati...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-12-01
|
| Series: | Journal of the Formosan Medical Association |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664620302424 |
| _version_ | 1828955226003996672 |
|---|---|
| author | Chen-Hua Liu Tung-Hung Su Chun-Jen Liu Pei-Jer Chen Ding-Shinn Chen Jia-Horng Kao |
| author_facet | Chen-Hua Liu Tung-Hung Su Chun-Jen Liu Pei-Jer Chen Ding-Shinn Chen Jia-Horng Kao |
| author_sort | Chen-Hua Liu |
| collection | DOAJ |
| description | Despite the excellent antiviral effects of direct acting antivirals (DAAs) for hepatitis C virus (HCV) infection with subsequent decrease of morbidity and mortality, a small proportion (5%) of the treated patients do not respond to first-line DAAs and have persistent viremia. Rescue therapy for patients with DAA failures is thus mandatory from both clinical and public health perspectives. Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX), a fixed-dose pangenotypic rescue agent, has been approved by the Food and Drug Administration (FDA) and European Medical Agency (EMA) for retreating HCV patients who fail prior DAA therapies. However, this agent has not been licensed by health authorities of Taiwan. Herein we reported two cases who successfully cleared HCV by using SOF/VEL/VOX plus ribavirin (RBV) after virologic failures to first-line pangenotypic SOF/VEL. Furthermore, we discussed the current unmet medical needs and clinical implications of SOF/VEL/VOX on the perspectives of HCV elimination in Taiwan. |
| first_indexed | 2024-12-14T07:46:55Z |
| format | Article |
| id | doaj.art-7236bc32588c4c37a672614b8d71cba1 |
| institution | Directory Open Access Journal |
| issn | 0929-6646 |
| language | English |
| last_indexed | 2024-12-14T07:46:55Z |
| publishDate | 2020-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the Formosan Medical Association |
| spelling | doaj.art-7236bc32588c4c37a672614b8d71cba12022-12-21T23:10:52ZengElsevierJournal of the Formosan Medical Association0929-66462020-12-011191218711875Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in TaiwanChen-Hua Liu0Tung-Hung Su1Chun-Jen Liu2Pei-Jer Chen3Ding-Shinn Chen4Jia-Horng Kao5Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan; Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Douliou, TaiwanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, Taipei, TaiwanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, Taipei, TaiwanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, TaiwanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan; Genomics Research Center, Academia Sinica, Taipei, TaiwanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan; Corresponding author. Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine and Hospital, 7 Chung-Shan South Road, Taipei, 10002, Taiwan. Fax: +886 2 23825962.Despite the excellent antiviral effects of direct acting antivirals (DAAs) for hepatitis C virus (HCV) infection with subsequent decrease of morbidity and mortality, a small proportion (5%) of the treated patients do not respond to first-line DAAs and have persistent viremia. Rescue therapy for patients with DAA failures is thus mandatory from both clinical and public health perspectives. Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX), a fixed-dose pangenotypic rescue agent, has been approved by the Food and Drug Administration (FDA) and European Medical Agency (EMA) for retreating HCV patients who fail prior DAA therapies. However, this agent has not been licensed by health authorities of Taiwan. Herein we reported two cases who successfully cleared HCV by using SOF/VEL/VOX plus ribavirin (RBV) after virologic failures to first-line pangenotypic SOF/VEL. Furthermore, we discussed the current unmet medical needs and clinical implications of SOF/VEL/VOX on the perspectives of HCV elimination in Taiwan.http://www.sciencedirect.com/science/article/pii/S0929664620302424Hepatitis C virusDirect acting antiviralSofosbuvirVelpatasvirVoxilaprevir |
| spellingShingle | Chen-Hua Liu Tung-Hung Su Chun-Jen Liu Pei-Jer Chen Ding-Shinn Chen Jia-Horng Kao Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan Journal of the Formosan Medical Association Hepatitis C virus Direct acting antiviral Sofosbuvir Velpatasvir Voxilaprevir |
| title | Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan |
| title_full | Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan |
| title_fullStr | Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan |
| title_full_unstemmed | Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan |
| title_short | Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan |
| title_sort | sofosbuvir velpatasvir voxilaprevir plus ribavirin for chronic hepatitis c patients with direct acting antiviral failures implications for viral elimination in taiwan |
| topic | Hepatitis C virus Direct acting antiviral Sofosbuvir Velpatasvir Voxilaprevir |
| url | http://www.sciencedirect.com/science/article/pii/S0929664620302424 |
| work_keys_str_mv | AT chenhualiu sofosbuvirvelpatasvirvoxilaprevirplusribavirinforchronichepatitiscpatientswithdirectactingantiviralfailuresimplicationsforviraleliminationintaiwan AT tunghungsu sofosbuvirvelpatasvirvoxilaprevirplusribavirinforchronichepatitiscpatientswithdirectactingantiviralfailuresimplicationsforviraleliminationintaiwan AT chunjenliu sofosbuvirvelpatasvirvoxilaprevirplusribavirinforchronichepatitiscpatientswithdirectactingantiviralfailuresimplicationsforviraleliminationintaiwan AT peijerchen sofosbuvirvelpatasvirvoxilaprevirplusribavirinforchronichepatitiscpatientswithdirectactingantiviralfailuresimplicationsforviraleliminationintaiwan AT dingshinnchen sofosbuvirvelpatasvirvoxilaprevirplusribavirinforchronichepatitiscpatientswithdirectactingantiviralfailuresimplicationsforviraleliminationintaiwan AT jiahorngkao sofosbuvirvelpatasvirvoxilaprevirplusribavirinforchronichepatitiscpatientswithdirectactingantiviralfailuresimplicationsforviraleliminationintaiwan |